Skip to content

RxSight, Inc. RXST Additional Paid-In Capital

Additional Paid-In Capital at other companies

LENSAR, Inc. logo
LENSAR, Inc.LNSR
$151.91M+2.4%
Schering-Plough logo
Schering-PloughSGP
$368.66M
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$1.83B+49.6%
Precision Optics Corporation logo
Precision Optics CorporationPOCI
$80.49M+17.2%
Bausch + Lomb logo
Bausch + LombBLCO
$8.58B+1.6%
Glaukos logo
GlaukosGKOS
$1.62B+6.3%

Other financials

Income statement

See full
Revenue$30.9M-18.5%
Gross profit$23.5M-17.1%
Operating income-$17.8M-67.0%
Net income-$15.9M-93.9%
EPS (diluted)-$0.38-90.0%

Balance sheet

See full
Cash & equivalents$17.6M-37.2%
Total debt$10.8M-10.1%
Total equity$267.3M-4.3%
Total assets$304.0M-2.9%

Cash flow

See full
Operating cash flow-$10.9M-23.3%
CapEx$759.0K+32.0%
Free cash flow-$11.7M-23.8%

Valuation

See full
Market cap$232.23M-56.8%
Enterprise value$225.49M-55.7%
P/S1.8×-1.8×

Profitability

See full
Gross margin77%+5.1pp
Operating margin-43.4%+128pp
Net margin-36.6%-867pp
FCF margin-16.9%+4.9pp

Returns & leverage

See full
Return on equity-17.1%+12.6pp
Debt / equity0.0×
Current ratio10.2×-2.5×

Where this comes from

Reported directly by RxSight, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: RxSight, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about RxSight, Inc.'s additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RxSight, Inc.'s additional paid-in capital?
RxSight, Inc. (RXST) reported additional paid-in capital of $944.24M in Q1 2026.
How has RxSight, Inc.'s additional paid-in capital changed year-over-year?
RxSight, Inc.'s additional paid-in capital increased by 3.8% year-over-year, from $909.55M to $944.24M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.